The Multiple Myeloma Channel

Explore the latest updates, including expert interviews, features, podcasts and e-learning

The Multiple Myeloma Channel on VJHemOnc receives independent medical education support from Janssen Pharmaceuticals (a Johnson & Johnson Company), Pfizer, Takeda, BMS, Karyopharm Therapeutics, Amgen and Legend Biotech. These supporters have no influence over the production of the content.

Welcome to The Multiple Myeloma Channel

In association with our world-leading Editorial Board, VJHemOnc bring you the latest updates in multiple myeloma, directly from the experts. As well as video interviews, you can listen to our podcasts, dive in to a roundtable discussion and e-learning, or read our feature articles.

The Myeloma Channel brings you the latest advances in therapy, including monoclonal antibodies, CAR-T cells, BiTEs, as well as up to date data and guidance on optimizing treatment combinations, sequencing and managing difficult to treat patient groups. The Myeloma Channel also delves in to the latest research in the understanding of precursor state progression, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma to active disease, the tumor microenvironment and more.


EHA 2022
ASCO 2022
COMy 2022
TCT 2022
AACR 2022
ICLE 2022


CAR-T & Cellular Therapy
Real-World Data
Trial Updates

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter